Conventional reductionist approaches have guided most of our understanding in disease diagnostic and treatment. However, most diseases are not consequence of perturbations in a single protein or metabolite, but rather of the effect that these perturbations have in their cellular context. The emerging field of network medicine offers a set of tools to explore molecular networks and to retrieve insights about mechanisms of different diseases. The study of the protein interactome, the map of physical interactions among human proteins, revealed that disease proteins tend to interact with each other, linking diseases to well-defined interactome neighborhoods. These disease-associated neighborhoods have been defined as disease modules, and they can uncover the biological significance of genes identified by genetic studies, reveal molecular mechanisms that connect different phenotypes, and help identify new pharmacological strategies for disease treatment. Therefore, network medicine offers a framework in which the complexity of different aspects of multiple sclerosis can be explored in an integrative fashion, which can ultimately provide insights about disease mechanisms and treatment.
MencheJSharmaAKitsakM, et al. Disease networks. Uncovering disease-disease relationships through the incomplete interactome. Science2015; 347(6224): 1257601.
5.
ChengFKovácsIABarabásiA-L. Network-based prediction of drug combinations. Nat Commun2019; 10: 1197.
6.
KovácsIALuckKSpirohnK, et al. Network-based prediction of protein interactions. Nat Commun2019; 10: 1240.
7.
HuttlinELBrucknerRJPauloJA, et al. Architecture of the human interactome defines protein communities and disease networks. Nature2017; 545(7655): 505–509.
8.
SahniNYiSTaipaleM, et al. Widespread Macromolecular interaction perturbations in human genetic disorders. Cell2015; 161(3): 647–660.
9.
ChenSFragozaRKleiL, et al. An interactome perturbation framework prioritizes damaging missense mutations for developmental disorders. Nat Genet2018; 50(7): 1032–1040.
10.
SharmaAMencheJChris HuangC, et al. A disease module in the interactome explains disease heterogeneity, drug response and captures novel pathways and genes in asthma. Hum Mol Genet2014; 24: 3005–3020.
11.
GohK-ICusickMEdo ValleIF, et al. The human disease network. Proc Natl Acad Sci U S A2007; 104: 8685–8690.
12.
ChengFDesaiRJHandyDE, et al. Network-based approach to prediction and population-based validation of in silico drug repurposing. Nat Commun2018; 9(1): 2691.
13.
ZhouXMencheJBarabasiAL, et al. Human symptoms–disease network. Nat Commun2014; 5: 4212.
14.
HaluADeDomenicoMArenasA, et al. The multiplex network of human diseases. NPJ Syst Biol Appl2019; 5: 15.
15.
HidalgoCABlummNBarabásiAL, et al. A dynamic network approach for the study of human phenotypes. PLoS Comput Biol2009; 5: e1000353.
16.
JensenABMoseleyPLOpreaTI, et al. Temporal disease trajectories condensed from population-wide registry data covering 6.2 million patients. Nat Commun2014; 5: 4022.
17.
RzhetskyAWajngurtDParkN, et al. Probing genetic overlap among complex human phenotypes. Proc Natl Acad Sci U S A2007; 104: 11694–11699.
18.
KhanAUddinSSrinivasanU. Comorbidity network for chronic disease: A novel approach to understand type 2 diabetes progression. Int J Med Inform. Epub ahead of print 9 April 2018. DOI: 10.1016/j.ijmedinf.2018.04.001.
19.
ChmielAKlimekPThurnerS. Spreading of diseases through comorbidity networks across life and gender. New J Phys2014; 16: 115013.
20.
KalgotraPShardaRCroffJM. Examining health disparities by gender: A multimorbidity network analysis of electronic medical record. Int J Med Inform2017; 108: 22–28.
21.
KlimekPAichbergerSThurnerS. Disentangling genetic and environmental risk factors for individual diseases from multiplex comorbidity networks. Sci Rep2016; 6: 39658.
22.
DozmorovMG. Disease classification: From phenotypic similarity to integrative genomics and beyond. Brief Bioinform. Epub ahead of print 22 June 2018. DOI: 10.1093/bib/bby049.
23.
SharmaAKitsakMChoMH, et al. Integration of molecular interactome and targeted interaction analysis to identify a COPD disease network module. Sci Rep2018; 8(1): 14439.
24.
GhiassianSDMencheJBarabasiAL. A DIseAse MOdule Detection (DIAMOnD) algorithm derived from a systematic analysis of connectivity patterns of disease proteins in the human interactome. PLoS Comput Biol2015; 11(4): e1004120.
25.
HuangJKCarlinDEYuMK, et al. Systematic evaluation of molecular networks for discovery of disease genes. Cell Syst2018; 6(4): 484–495.e5.
26.
LeisersonMDMVandinFWuH-T, et al. Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes. Nat Genet2015; 47(2): 106–114.
27.
SonawaneARWeissSTGlassK, et al. Network medicine in the age of biomedical big data. Front Genet2019; 10: 294.
28.
SharmaAHaluADecanoJL, et al. Controllability in an islet specific regulatory network identifies the transcriptional factor NFATC4, which regulates Type 2 Diabetes associated genes. NPJ Syst Biol Appl2018; 4: 25.
29.
LeeSZhangCKilicarslanM, et al. Integrated network analysis reveals an association between plasma mannose levels and insulin resistance. Cell Metab2016; 24(1): 172–184.
30.
PichlmairAKandasamyKAlvisiG, et al. Viral immune modulators perturb the human molecular network by common and unique strategies. Nature2012; 487(7408): 486–490.
31.
TaşanMMussoGHaoT, et al. Selecting causal genes from genome-wide association studies via functionally coherent subnetworks. Nat Methods2014; 12: 154–159.
32.
AkulaNBaranovaASetoD, et al. A network-based approach to prioritize results from genome-wide association studies. PLoS ONE2011; 6: e24220.
33.
WangRSLoscalzoJ. Illuminating drug action by network integration of disease genes: A case study of myocardial infarction. Mol Biosyst2016; 12(5): 1653–1666.
34.
GuneyEMencheJVidalM, et al. Network-based in silico drug efficacy screening. Nat Commun2016; 7: 10331.
35.
WooJHShimoniYYangWS, et al. Elucidating compound mechanism of action by network perturbation analysis. Cell2015; 162(2): 441–451.
36.
do ValleIFMenichettiGSimonettiG, et al. Network integration of multi-tumour omics data suggests novel targeting strategies. Nat Commun2018; 9(1): 4514.
37.
BaranziniSEGalweyNWWangJ, et al. Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Hum Mol Genet2009; 18(11): 2078–2090.
38.
GiacaloneGClarelliFOsiceanuAM, et al. Analysis of genes, pathways and networks involved in disease severity and age at onset in primary-progressive multiple sclerosis. Mult Scler2015; 21(11): 1431–1442.
39.
MadireddyLPatsopoulosNACotsapasC, et al. A systems biology approach uncovers cell-specific gene regulatory effects of genetic associations in multiple sclerosis. Nat Commun2019; 10: 2236.
40.
Safari-AlighiarlooNRezaei-TaviraniMTaghizadehM, et al. Network-based analysis of differentially expressed genes in cerebrospinal fluid (CSF) and blood reveals new candidate genes for multiple sclerosis. PeerJ2016; 4: e2775.
41.
KatiyarASharmaSSinghTP, et al. Identification of shared molecular signatures indicate the susceptibility of endometriosis to multiple sclerosis. Front Genet2018; 9: 42.
42.
MechelliRUmetonRPolicanoC, et al. A “candidate-interactome” aggregate analysis of genome-wide association data in multiple sclerosis. PLoS ONE2013; 8: e63300.
